The Quad single-tablet regimen, an all-in-one pill containing the experimental integrase inhibitor elvitegravir plus two other antiretroviral drugs and a novel boosting agent, was as effective as the widely used Atripla combination but with fewer neuropsychiatric side-effects, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections last week in Seattle. In a companion study the Quad regimen also matched boosted atazanavir (Reyataz).

read the full story